Affibody Medical: Affibody to Participate in Upcoming Healthcare Investor Conferences
27 augusti, 14:00
27 augusti, 14:00
Stockholm, Sweden, August 27, 2026. Affibody AB (“Affibody”), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced participation in two upcoming investor conferences, delivering an update on clinical data from the ongoing Phase 1 study evaluating the RLT candidate, ABY-271, in patients with HER2-positive metastatic breast cancer.
Morgan Stanley 24th Annual Global Healthcare Conference (New York City)
4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit (New York City)
About Affibody
Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.
The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.
Affibody’s main shareholder, Patricia Industries, is a part of Investor AB.
Further information can be found at: www.affibody.com.
Investor Relations
Leigh Salvo, New Street Investor Relations, +1 510 693 5238, leigh@newstreetir.com
Media Contact
Richard Hayhurst, 59° North Communications, +44 (0) 7711 8215727, richard.hayhurst@59north.bio
Affibody Contact
David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044
27 augusti, 14:00
Stockholm, Sweden, August 27, 2026. Affibody AB (“Affibody”), a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs), today announced participation in two upcoming investor conferences, delivering an update on clinical data from the ongoing Phase 1 study evaluating the RLT candidate, ABY-271, in patients with HER2-positive metastatic breast cancer.
Morgan Stanley 24th Annual Global Healthcare Conference (New York City)
4th Annual Oppenheimer Targeted Radiopharmaceutical Therapies Summit (New York City)
About Affibody
Affibody is a clinical stage radiopharmaceutical company developing next generation Radioligand Therapies (RLTs) designed to deliver highly selective tumor targeting across a wide range of cancers. Leveraging decades of innovation in Affibody® molecule discovery and engineering, together with deep understanding of the RLT field, the company is advancing a novel pipeline focused on oncology indications with high unmet medical need. Affibody’s lead RLT candidate, ABY-271, is currently being evaluated in a first-in-human clinical study in HER2-positive metastatic breast cancer.
The Affibody® platform has also demonstrated clinical value in immunology and inflammation, with multiple programs being advanced through strategic partnerships.
Affibody’s main shareholder, Patricia Industries, is a part of Investor AB.
Further information can be found at: www.affibody.com.
Investor Relations
Leigh Salvo, New Street Investor Relations, +1 510 693 5238, leigh@newstreetir.com
Media Contact
Richard Hayhurst, 59° North Communications, +44 (0) 7711 8215727, richard.hayhurst@59north.bio
Affibody Contact
David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044
Fonder

Sweco
Börsen

Privatekonomi
Stegra
Fonder

Sweco
Börsen

Privatekonomi
Stegra
1 DAG %
Senast
OMX Stockholm 30
1,05%
(vid stängning)
Fonder
3 oktober, 07:00
Hävstångsfonderna som ger extra fart
Matpriser
3 oktober, 07:00
Privatekonomen: Så kapar du matkostnaden med 30%
Laxbolag
2 oktober, 13:53
Goldman Sachs ser ny lönsamhetsera för laxsektorn
OMX Stockholm 30
1 DAG %
Senast
3 260,51